<DOC>
	<DOCNO>NCT01742676</DOCNO>
	<brief_summary>The purpose study evaluate compare safety efficacy two drug ( ADVAGRAF速 PROGRAF速 group ) patient receive renal transplantation .</brief_summary>
	<brief_title>A Single Center , Open-label , Randomized , Pilot Study Evaluate Safety Efficacy Tacrolimus Modified Release , ADVAGRAF速 , Versus Tacrolimus Twice Daily , PROGRAF速 Stable Renal Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Only patient meet follow inclusion criterion enrol . 1 . Patients receive kidney least within 12 month study enrollment ( deceased living donor ) 2 . Patients whose tacrolimus dose change least 12 week study enrollment whose minimum blood tacrolimus concentration mean value within 310 ng/ml 3 . Female patient show negative result serum pregnancy test agree use effective contraceptive method study period 4 . Patients clinically stable base judgment investigator 5 . Patients give enough information regard study , understood objective risk study , sign informed consent form Patients fall follow criterion enrol study . 1 . Patients receive organ except kidney 2 . Patients show acute rejection reaction within 12 week enrollment show acute rejection reaction require antilymphocyte antibody therapy within 24 week 3 . Patients diagnose newly develop malignant tumor ( Patients successfully treat squamous cell/basal cell carcinoma enrol , though . ) 4 . Patients know allergy investigational drug ( test/control drug ) tacrolimus 5 . Patients unstable medical condition may affect evaluation study 's objective base investigator 's judgment 6 . Patients form drug abuse mental illness might complicate communication investigator base investigator 's judgment 7 . Patients currently participate another clinical trial receive investigational drug another trial within 28 day enrollment 8 . Patients receive prohibit concomitant medication receive medication within 28 day enrollment 9 . Patients pregnant breastfeed 10 . Patients HIVpositive 11 . Patients consider noncompliant schedule study visit protocol 12 . Patients abnormal kidney function serum creatinine level high 1.6 mg/dL/GFR ( MDRD ) less 30 mL/min screen visit 13 . Patients `` Creeping creatinine '' ( 20 % increase creatinine six month enrollment ) 14 . Patients abnormal liver function : i.e. , whose SGPT/ALT and/or SGOT/AST and/or bilirubin twice high normal range center , liver cirrhosis 15 . Patients underlying disease focal segmental glomerulosclerosis ( FSGS ) type II membranoproliferative glomerulonephritis ( Type II MPGN )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>tacrolimus</keyword>
	<keyword>kidney</keyword>
</DOC>